Show simple item record

dc.contributor.authorBurchill, SAen_US
dc.contributor.authorKinsey, SEen_US
dc.contributor.authorPicton, Sen_US
dc.contributor.authorRoberts, Pen_US
dc.contributor.authorPinkerton, CRen_US
dc.contributor.authorSelby, Pen_US
dc.contributor.authorLewis, IJen_US
dc.date.accessioned2018-09-17T15:18:51Z
dc.date.issued2001-01en_US
dc.identifier1en_US
dc.identifier.citationMEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 pp. 213 - 219en_US
dc.identifier.issn0098-1532en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2755
dc.identifier.doi10.1002/1096-911X(20010101)36:1<213::AID-MPO1052>3.3.CO;2-0en_US
dc.description.abstractBackground. Despite treatment with high-dose myeloblative chemotherapy and peripheral blood stem cell (PBSC) rescue, a high proportion of children with neuroblastoma relapse and die. Re-infusion of PBSC contaminated with tumour at the time of autologous transplantation may play a significant role in this relapse. In this study the frequency of tumour contamination in PB from children with neuroblastoma has been investigated. Procedure. Minimal residual disease was measured using RT-PCR for tyrosine hydroxylase (TH) mRNA in PBSCs from patients with advanced neuroblastoma. PBSCs from 18 patients in complete clinical remission were studied. Results. Studies in other cancers have suggested minimal contamination of PBSCs with tumour cells; TH mRNA was detected by RT-PCR in 50% (9/18) of PBSC harvests. Seventy-seven percent (7/9) of patients with TH mRNA in PBSC died of disease compared to 44% (4/9) who were TH mRNA-negative. Conclusions. Therefore, the presence of TH mRNA in PBSCs appeared to be associated with an unfavourable outcome, although this was not statistically significant. In summary, RT-PCR for TH mRNA is a sensitive method for the identification of tumour cells in PBSC harvest. The presence of TH mRNA in PBSC harvest may reflect disease status and be associated with an unfavourable outcome, although long-term clinical outcome studies in a larger patient cohort are required. Med. Pediatr. Oncol. 36:213-219, 2001. (C) 2001 Wiley-Liss, Inc.en_US
dc.format.extent213 - 219en_US
dc.titleMinimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastomaen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/1096-911X(20010101)36:1<213::AID-MPO1052>3.3.CO;2-0en_US
rioxxterms.licenseref.startdate2001-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfMEDICAL AND PEDIATRIC ONCOLOGYen_US
pubs.notesAdvances in Neuroblastoma Research Meeting, BATH, ENGLAND, JUN 15-17, 1998 researcherid-numbers: pinkerton, ross/I-4808-2014 unique-id: ISI:000166167300052en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume36en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorPinkerton, Rossen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record